Tumours were treated with a 14 day regimen that combined BAY 1895344 together with the ALK TKI lorlatinib (3 days BAY 1895344 25 mg/kg b.i.d. (twice per day), 4 days lorlatinib 10 mg/kg b.i.d., 3 days combination, 4 days lorlatinib) (Fig. 6a). The gene discussed is ALK; the disease is neoplasm.